Graduate Research Assistant
Office: EBB 3110
Research Focus: synthetic nanoparticle antibody for cancer immunotherapy
Antibodies have been used as immuno-checkpoint blockade and direct-targeting strategies for cancer and achieved phenomenal success in clinical trials. However, the development cycle for monoclonal antibodies (MAbs) are complex, time- and cost-consuming. Moreover, the biological and physical properties of MAbs limited their development and application in some cases, such as targeting myeloid-derived suppressor cells, or solid tumors. We are developing an artificial antibody using Janus nanoparticles coated with ligands, one that can recognize specific cell-surface markers and the other that can trigger innate immune responses, i.e. antibody-dependent cellular cytotoxicity. These synthetic nanoparticle antibodies (SNAbs) can be fabricated easily at a much reduced cost and within a shorter time period. They can be tailored freely to work on different targets of interest and overcome the limitations for trafficking to disease sites in vivo.